ClinicalTrials.gg
RecruitingNCT07861321Updated Oct 19, 2026

A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children

An interventional study of Nano Silver Fluoride / NSF in Dental Caries, sponsored by A.T. Still University of Health Sciences. Recruiting at 1 site in United States. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by A.T. Still University of Health Sciences · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 19, 2026Now RecruitingStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Dental Caries with a site in United States — 17 open to participants now, 20 under way, 3 of them phase 3. Dental Caries · United States.

Planned enrollment
78th of 169
72 · median 60
Started
2026
with 9 others
No phase
111 of 194
14 open now
Primary completion
2027-10
later than 11 of 19 live
Registered
192nd of 194
by date

Among the 194 studies in Dental Caries with a site in United States, this one is the 78th largest by planned enrollment of the 169 interventional ones that give a count, is one of 10 that started in 2026, is one of 111 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 192nd registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

17 of the 194 studies in Dental Caries with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Dental Caries with a site in United States, or all of them as a file.
02

Study summary

This study, titled "A Randomized Controlled Trial to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children" (Study Number: ATSU-YI-NSF 2025), is sponsored by Young Innovations and conducted at the Arizona School of Dentistry \& Oral Health (ASDOH) at A.T. Still University in Mesa, Arizona, under Principal Investigator Marc Shlossman, DDS, MS. The primary objective is to validate and compare the cariostatic efficacy of Nano Silver Fluoride (ClearDefense®) against Silver Diamine Fluoride (AdvantageArrest®) in pediatric dental patients with active carious lesions on primary molars and first permanent molars. Designed as a non-inferiority trial, it evaluates whether Nano Silver Fluoride provides comparable caries-arresting effects while assessing patient, parent, and provider acceptance, tooth color changes, and overall product safety. The trial is structured as a six-month, double-blind, parallel-group, single-site randomized controlled study with an optional twelve-month follow-up visit. To achieve a target sample size of 60 evaluable subjects (30 per treatment group) while accounting for a projected 20% dropout rate, a total of 72 pediatric participants will be recruited. Subjects are randomly assigned to treatment arms using an online random number generator. Allocation concealment and double-blinding are maintained by a third-party study coordinator who prepares treatment supplies on preset trays, keeping trial investigators, outcome examiners, and participants masked to product identity. Eligible participants include medically healthy children aged 6 to 10 years who present with at least one primary molar or permanent first molar containing active occlusal or proximal caries classified as ICDAS II Stage 3 through 6. Children and their parents or guardians must read and understand English or Spanish, provide written assent and consent, and agree to attend all required study visits. Exclusion criteria apply to children with known allergies to fluoride or silver, significant systemic conditions, ulcerative oral lesions, or conditions reducing salivary flow, as well as target teeth with loose roots, pulpal involvement, or existing restorations. At the baseline visit, active carious lesions receive a single topical application of either ClearDefense® (3% sodium fluoride + 0.2% silver ion) or AdvantageArrest® (38% silver diamine fluoride) for at least one minute. Mandatory study appointments occur at baseline, 3 months, 6 months, and an optional 12 months, incorporating clinical oral examinations, tooth cleaning, radiographs, intraoral photographs, and digital tooth shade assessments using a Vita Easyshade V spectrophotometer. The primary response variable is the clinical status of the carious lesion (active vs. arrested) measured at 3 and 6 months. Secondary outcome measures include pre- and post-treatment tooth color changes, parent-reported quality of life via the Early Childhood Oral Health Impact Scale (ECOHIS), child satisfaction regarding taste (using the TASTY scale at baseline) and tooth appearance, parent treatment acceptability, investigator ease-of-use feedback at study closeout, and documentation of adverse events including soft tissue staining or localized pain.

03

Conditions studied

  • Dental Caries

Browse trials for

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between the ages of 6 to 10 years.
  • Are medically healthy.
  • Have a minimum of one permanent deciduous molar tooth and one permanent first molar with an occlusal and/or proximal carious lesion classified as ICDAS II (International Caries Detection and Assessment System) Stage 3-4 (moderate caries) or Stage 5-6 (advanced caries).
  • Must be able to understand and be willing to provide written child assent and parent/guardian consent for study participation.
  • Must be willing and able to attend all study visits.
  • Must be able to read and understand English and/or Spanish.
  • Must be willing to provide feedback about study outcomes in their child (patient-reported/parent-reported outcome measures).

Exclusion criteria

Exclusion Criteria

  • Have a known sensitivity/allergy to fluoride, silver or other heavy-metal ions.
  • Have a significant medical history, such as cardiac conditions that require antibiotic prophylaxis prior to dental treatment, or poorly controlled/uncontrolled diabetes.
  • Present with ulcerative gingivitis or aphthous stomatitis.
  • Have a history of full mouth gingivectomy.
  • Chronically take medications that reduce salivary flow, including stimulants for ADHD and antihistamines for seasonal allergies.
  • Have a history of systemic disease that reduces salivary flow, such as an disease.
  • Deciduous molars are loose at the initial screening examination visit.
  • Deciduous molars or first permanent molars with occlusal and/or proximal caries have an existing restoration or recurrent caries at the site of potential study treatment.
  • Deciduous molars or first permanent molars have extensive occlusal and/or proximal caries with pulpal involvement and/or require surgical intervention for treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Experimental Arm (Nano Silver Fluoride / NSF)

    Participants receive a single topical application of ClearDefense® (3% sodium fluoride + 0.2% silver ion) to active carious lesions

    Device: Nano Silver Fluoride / NSF

  • Active comparator
    Active Comparator Arm (Silver Diamine Fluoride / SDF)

    Participants receive a single topical application of AdvantageArrest® (38% silver diamine fluoride) to active carious lesions

    Device: Nano Silver Fluoride / NSF

Interventions

  • DeviceNano Silver Fluoride / NSF

    The intervention consists of a single topical application of either ClearDefense® Nano Silver Fluoride (3% sodium fluoride + 0.2% silver ion) or AdvantageArrest® Silver Diamine Fluoride (38% SDF) directly onto active carious lesions on primary molars or first permanent molars. Prior to treatment, visible plaque is removed using a tapered brush prophy angle, baseline tooth shade is recorded, and the target teeth are isolated with cotton rolls and gauze before being dried with an air-water syringe. To maintain blinding, a study coordinator dispenses two drops of the assigned agent into a dappen dish, and the study investigator applies the product across the entire carious lesion using a microbrush, allowing it to sit for at least one minute while soft tissues are retracted to avoid staining. Finally, excess product is wiped away with gauze or a cotton roll, and participants are instructed to refrain from eating or drinking for at least 30 minutes post-application.

06

What researchers measure

Primary outcomes

  1. Change in the Carious Lesion Status after Treatment

    Carious teeth will be determined using ICDAS II criteria, Stage 3-4 (moderate stage caries) or Stage 5-6 (advanced stage caries) on the occlusal and/or proximal surface(s). The carious lesion is deemed "active" if there is a greater likelihood of progression into the deeper layers of tooth structure. After treatment with the randomly assigned study intervention, using a ball-tip probe, a carious lesion will be scored as active, if the lesion feels soft or leathery on gently probing the dentin. The carious lesion will be scored as arrested if the lesion feels hard on gently probing the dentin. The initial examiner who applies the intervention will be blinded to the study product and will record their score(s) for each treated lesion. A second examiner will be blinded to the study product and to the score(s) recorded by the initial examiner; they will record their score(s) separately.

    Time frame: Change in carious lesion status post-treatment from Baseline to 3 months, and 3 months to 6 months. There is an optional assessment for volunteers to return to assess change in carious lesion status from 6 months to 12 months.

Secondary outcomes

  1. Change in Tooth Color/Shade from Baseline to Post-Treatment

    VITA Easyshade® V uses spectrophotometry in the 400-700 nm range to objectively measure the light reflectance of natural teeth, ceramic restorations, and bleached teeth It is designed for fast, reliable, and reproducible shade matching, eliminating the subjectivity of traditional visual shade guides. There is a standardized set of 16 natural, empirically induced tooth shades that allow dentists and dental laboratories to match restorations to natural tooth color with high accuracy. How the system works: * A, B, C, D = the lettering represents hue groups (color tone) * 1-4 = the numbering represents value steps or gradients from lightest to darkest; 1 represents the lightest color, while 4 represents the darkest color * A1-A4: reddish brownish tones * B1-B4: reddish yellowish tones * C1-C4: greyish tones * D2-D4: reddish grey tones

    Time frame: Tooth color/shade will be measured at Baseline pre- and post-teatment; then comparing post-treatment to color/shade at 3 months and at 6 months. There is an option for volunteers to return to assess tooth color/shade from post-treatment at 12 months

  2. Early Childhood Oral Health Impact Scale (ECOHIS)

    The validated ECOHIS will be used to assess the impact of oral health problems and related treatment experiences on the quality of life of study participants and their families. The scale consists of six subscales: Child Symptom Domain, Child Function Domain, Child Psychological Domain, Child Self-Image/social Interaction Domain, Parent Distress Domain, and Family Function Domain. The ECOHIS consists of 13 items that are scored using a 6 point Likert scale: Response options: 1. Never, 2. Hardly ever, 3. Occasionally, 4. Often, 5. Very often, and 6. Don't know. Parents/guardians will be guided to complete the ECOHIS using the following instructions: "Problems with the teeth, mouth or jaws and their treatment can affect the well-being and everyday lives of children and their families. For each of the following questions, please circle the number next to the response that best describes your child's experiences or your own. Consider the child's entire life from birth until now.

    Time frame: Changes in ECOHIS will be compared from Baseline to 6 months, with an optional 12 month visit when ECOHIS scores will be compared to both Baseline and 6 months.

  3. Status of Child Behavior During Treatment

    The child subject's behavior during study product application will be documented as either cooperative or uncooperative (dichotomous). Lack of cooperation could affect optimal product placement.

    Time frame: The status of the child's behavior is recorded post-treatment at the initial (Baseline) visit only.

  4. Status of Child Satisfaction with Appearance of Treated Teeth (Patient Reported Outcome Measure)

    Child subjects' satisfaction with the appearance of their teeth that have had the study treatment will be captured by asking the child to select a picture that depicts choices using a 3-item Likert Scale: Happy (smiley face), Unsure (thinking face with a question mark above it), or Sad (frowning face). A score will be assigned to each choice: Happy (3), Unsure (2), Sad (1).

    Time frame: Child satisfaction with the appearance of their teeth will be recorded immediately post-treatment at Baseline, then compared to Baseline at 3 months and 6 months. There will be an optional 12 month score to compare against the Baseline score.

  5. Status of Child Satisfaction with Product Taste (Patient Reported Outcome Measure)

    The child will be asked to use the validated TASTY scale to assess their satisfaction with product taste. The TASTY scale is a seven-item Likert scale, with visual graphics that are then coded numerically for a taste score.

    Time frame: The child's TASTY score will be recorded immediately post-treatment at the initial (Baseline) visit only.

  6. Parent/Guardian Satisfaction with Acceptability of Treatment

    Parent/guardian acceptability of treatment will be measured using a published, 4-item, 5-level Likert-scale assess feelings about the application procedure. The scale is scored from Strongly Agree to Strongly Disagree for the following items: * The study product application is an easy process. * I am comfortable with discoloration of cavities after study product placement. * The study product application as pain free for my child. * The taste of the study product was acceptable to my child.

    Time frame: Parent/guardian satisfaction with acceptability of treatment will be recorded immediately post-treatment at the initial (Baseline) visit, with scores compared to Baseline at 3 months, 6 months, and an optional 12 months.

  7. Provider Satisfaction with Product Use

    Sstudy examiners will provide their feedback about ease of product use/ performance using a Likert scale, scored from Strongly Agree to Strongly Disagree. * It was easy for me to identify which product was applied due to the degree of post-treatment staining of the carious lesion. * " " to the degree of post-treatment staining of the surrounding soft tissues. * There was a noticeable difference between the two products based on their efficacy with arresting the carious lesion(s). The same Likert scale will be used to score each product (SDF and NSF): * The study product application was easy. * " " was time-efficient. * The study product performance with arresting caries was satisfactory with one treatment. * The children seemed to tolerate this product well. * " " appeared dissatisfied with the appearance of their tooth/teeth after treatment. * " " with the taste of the product after treatment. * I intend to continue use of the product...

    Time frame: The study examiners will complete the Provider Satisfaction with Product Use at the end of the study only (6 months, and/or optional 12 months)

  8. Incidence of Adverse Events

    The presence/absence of adverse events will be assessed and documented immediately after product application and at all timepoints. Adverse events include taste alteration, pulpal and soft tissue irritation, permanent staining of adjacent teeth and restorations, and temporary staining of soft tissues (intraoral: mucosa, tongue, gingiva; extraoral: lips, cheeks). Adverse events are scored dichotomously (present/absent). Photography may be used as part of documentation for severe adverse events.. Severe adverse events will be managed accordingly and reported to the IRB, sponsor and appropriate regulatory bodies.

    Time frame: Adverse events will be reported immediately post-treatment at the initial (Baseline) visit, and at all study visits: 3 months, 6 months, and optional 12 month visit.

  9. Status of Child's Oral Hygiene Behaviors

    The child subject's oral hygiene behaviors will be assessed for the potential to influence caries risk. Behaviors will be reported by the children's parents/guardians and includes: Fquency of daily toothbrushing (None 1, 2, more than 2 times); How does their child brush their teeth (Child brushes their own teeth (unsupervised brushing), Both the child and parent brush the child's teeth, Parent brushes the child's teeth, Child brushes their own teeth but the parent watches (supervised brushing); Use of fluoridated toothpaste (yes, no, I don't know); Brand of toothpaste used (enter brand name or I don't know); Drinks fluoridated water (yes, no); and zipcode of primary residence (enter 5 digits - used to confirm if city/town has community-fluoridated water).

    Time frame: The child subject's oral hygiene behaviors are assessed at Baseline only.

  10. Status of Child's Daily Sugar Consumption Score

    The child subject's parent/guardian will report the child's intake of eight different sugary foods and beverages. Higher scores represent higher caries risk. The eight categories of foods and beverages assessed include: Candies, fruit roll-ups; Cookies and cakes; Fruit: fresh fruit, fruit cocktail; Sugar-added chewing gums; Jam, Jelly or Honey; Carbonated beverages (sodas); Sugar-sweetened milk; and Sweetened hot drinks. The paret/guardian will mark each category that their child consumes on a daily basis. The number of categories will be calculated and documented.

    Time frame: The Child's Daily Sugar Consumption Score will be recorded at the initial (Baseline) visit only.

  11. Number of Child Subject's Dental Visits in the Past Year

    The number of dental visits that the child had in the past year will be documented, and whenever possible, will be confirmed via chart and/or provider audit. Receipt of regular professional care may influence caries risk.

    Time frame: The number of the child subject's dental visits in the past year will be recorded at the initial (Baseline) visit only.

07

Study locations

1 of 1 sites recruiting
  • Arizona School of Dentistry & Oral Health (ASDOH), A.T. Still University
    Mesa, Arizona 85206, United States
    Recruiting
08

References and documents

Publications

  • Mortazavi SMJ. Re: Are electromagnetic fields in incubators a risk factor for autism? Acta Paediatr. 2017 Dec;106(12):2063. doi: 10.1111/apa.14055. Epub 2017 Sep 24. No abstract available. PubMed 28862780 ↗
  • Viana PHL, Schvarcz CA, Danics LO, Besztercei B, Aloss K, Bokhari SMZ, Giunashvili N, Bocsi D, Koos Z, Benyo Z, Hamar P. Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model. Sci Rep. 2024 Apr 8;14(1):8241. doi: 10.1038/s41598-024-57659-x. PubMed 38589452 ↗
  • Cheng Y, Wang T, Lv X, Li R, Yuan L, Shen J, Li Y, Yan T, Liu B, Wang L. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer. Cancer Manag Res. 2020 Mar 19;12:2069-2078. doi: 10.2147/CMAR.S245425. eCollection 2020. PubMed 32256114 ↗
  • Pahel BT, Rozier RG, Slade GD. Parental perceptions of children's oral health: the Early Childhood Oral Health Impact Scale (ECOHIS). Health Qual Life Outcomes. 2007 Jan 30;5:6. doi: 10.1186/1477-7525-5-6. PubMed 17263880 ↗
  • Michaeli L, Davis DM, Foxton R. Denture loss: an 8-month study in a community dental setting. Gerodontology. 2007 Jun;24(2):117-20. doi: 10.1111/j.1741-2358.2007.00133.x. PubMed 17518960 ↗
  • Nezam S, Mukherjee CG, Shukla JN, Jha A, Khan SA, Tanwar AS. Comparative Evaluation of Efficacy of Obturation Techniques in Deciduous Teeth Using Cone-beam Computed Tomography: An In Vivo Study. Int J Clin Pediatr Dent. 2021 Jan-Feb;14(1):75-80. doi: 10.5005/jp-journals-10005-1897. PubMed 34326588 ↗
  • Huang X, Yang X, Huang J, Wei L, Mao Y, Li C, Zhang Y, Chen Q, Wu S, Xie L, Sun C, Zhang W, Wang J. Correction: Human amnion mesenchymal stem cells promote endometrial repair via paracrine, preferentially than transdifferentiation. Cell Commun Signal. 2024 Jun 13;22(1):326. doi: 10.1186/s12964-024-01706-7. No abstract available. PubMed 38872205 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made available to outside researchers, as the protocol limits data access strictly to authorized study personnel and the study sponsor. All clinical findings will be de-identified, maintained on secure university servers, and reported exclusively in aggregate form to safeguard participant confidentiality. Furthermore, in accordance with institutional data management procedures, all electronic study records will be permanently deleted three years following trial completion.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2028 → Oct 2027, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 6, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Oct 31, 2027was Oct 2028
CompletionEst.
Oct 31, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
1 site added — first site in United States
Show site
  • Arizona School of Dentistry & Oral Health (ASDOH), A.T. Still University · Mesa, United States
Oct 19, 2026
Primary completion
Oct 31, 2028→Oct 31, 2027
Oct 19, 2026
Interventions
Added Device: Nano Silver Fluoride / NSF; removed Drug: Nano Silver Fluoride / NSF
Oct 19, 2026
Documents
Oct 19, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    Documents Study protocol ↗ posted
    1 site added — first site in United States
    Show site
    • Arizona School of Dentistry & Oral Health (ASDOH), A.T. Still University · Mesa, United States
    Primary completion Oct 31, 2028→Oct 31, 2027
    Interventions Added Device: Nano Silver Fluoride / NSF; removed Drug: Nano Silver Fluoride / NSF
    + 2 other changes: index terms and oversight details
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861321
Lead sponsor
A.T. Still University of Health Sciences
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 1, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Marc Shlossman Associate Director of Clinical Research, DDS, MS
Contact
mshlossman@atsu.edu
(480) 248-8151
Ann Eshenaur Spolarich Professor and Assistant Dean for Research, RDH, PhD
Contact
ASpolarich@atsu.edu
(480) 248-8153

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion